UY33132A - Proteínas solubles para su uso terapéutico - Google Patents
Proteínas solubles para su uso terapéuticoInfo
- Publication number
- UY33132A UY33132A UY33132A UY33132A UY33132A UY 33132 A UY33132 A UY 33132A UY 33132 A UY33132 A UY 33132A UY 33132 A UY33132 A UY 33132A UY 33132 A UY33132 A UY 33132A
- Authority
- UY
- Uruguay
- Prior art keywords
- therapeutic use
- soluble proteins
- proteins
- soluble
- therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28900709P | 2009-12-22 | 2009-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY33132A true UY33132A (es) | 2011-07-29 |
Family
ID=43706449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY33132A UY33132A (es) | 2009-12-22 | 2010-12-22 | Proteínas solubles para su uso terapéutico |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20130011401A1 (pt) |
| EP (1) | EP2516458A1 (pt) |
| JP (1) | JP2013514795A (pt) |
| KR (1) | KR20120107122A (pt) |
| CN (1) | CN102939303A (pt) |
| AR (1) | AR079701A1 (pt) |
| AU (1) | AU2010334974A1 (pt) |
| BR (1) | BR112012017164A2 (pt) |
| CA (1) | CA2785139A1 (pt) |
| MX (1) | MX2012007318A (pt) |
| TW (1) | TW201130511A (pt) |
| UY (1) | UY33132A (pt) |
| WO (1) | WO2011076781A1 (pt) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013031762A2 (pt) * | 2011-06-16 | 2016-09-13 | Novartis Ag | proteínas solúveis para utilização como terapêuticos |
| TWI593708B (zh) | 2011-09-26 | 2017-08-01 | 諾華公司 | 治療代謝病症之融合蛋白質 |
| UY34347A (es) | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
| DK3725807T3 (da) | 2012-12-03 | 2026-01-12 | Novimmune Sa | Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf |
| PL3575326T3 (pl) | 2012-12-17 | 2022-07-11 | Pf Argentum Ip Holdings Llc | Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc |
| WO2014121093A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| AU2014244083B2 (en) * | 2013-03-13 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| CA2906737C (en) | 2013-03-15 | 2023-08-15 | Amgen Inc. | Human pac1 antibodies |
| CN103204944B (zh) * | 2013-03-26 | 2014-05-28 | 江苏健德生物药业有限公司 | 用于治疗糖尿病的长效免疫融合蛋白 |
| CN103893743B (zh) * | 2014-04-10 | 2016-01-20 | 武汉大学 | 生长分化因子1（gdf1）基因在冠状动脉粥样硬化性心脏病中的功能和应用 |
| CN103898189B (zh) * | 2014-04-10 | 2015-10-28 | 武汉大学 | 信号调节蛋白α（SHSP-1）基因在心肌梗死中的应用 |
| NO2776305T3 (pt) * | 2014-04-23 | 2018-01-27 | ||
| WO2016001810A1 (en) | 2014-07-01 | 2016-01-07 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| WO2016023040A1 (en) * | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Sirp-alpha variant constructs and uses thereof |
| WO2016022971A1 (en) | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Sirp alpha-antibody fusion proteins |
| WO2016044224A1 (en) | 2014-09-15 | 2016-03-24 | Amgen Inc. | Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof |
| BR112017005631A2 (pt) * | 2014-09-19 | 2018-06-26 | City Of Hope | células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2 |
| AU2015364396B2 (en) | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
| CR20170510A (es) | 2015-04-10 | 2018-02-26 | Amgen Inc | Muteínas de interuquina 2 para la expansión de células t regulatorias |
| GB201506402D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| TWI737614B (zh) | 2015-06-11 | 2021-09-01 | 博錸生技股份有限公司 | 已編碼微載體及其製造方法以及用以進行多工分析之包含該等已編碼微載體之套件 |
| AU2016304794B2 (en) | 2015-08-07 | 2021-07-15 | ALX Oncology Inc. | Constructs having a SIRP-alpha domain or variant thereof |
| EA034582B1 (ru) * | 2015-08-07 | 2020-02-21 | АЭлЭкс ОНКОЛОДЖИ ИНК. | Конструкции варианта sirp-альфа и их применение |
| AU2016310348B2 (en) | 2015-08-26 | 2023-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist |
| JP6981973B2 (ja) * | 2015-10-01 | 2021-12-17 | ヒート バイオロジクス，インコーポレイテッド | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
| US10822408B2 (en) | 2015-12-15 | 2020-11-03 | Amgen Inc. | PACAP antibodies and uses thereof |
| US20170210803A1 (en) * | 2016-01-21 | 2017-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with combinations of immunoregulatory agents |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| WO2018005226A2 (en) | 2016-06-22 | 2018-01-04 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
| CA3042581A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| JP7179743B2 (ja) * | 2017-02-17 | 2022-11-29 | オーエスイー・イミュノセラピューティクス | 抗ＳＩＲＰｇ抗体の新規の使用 |
| BR112020001653A2 (pt) | 2017-07-26 | 2020-07-21 | Forty Seven, Inc. | anticorpos anti-sirp-alfa e métodos relacionados |
| JP7262440B2 (ja) * | 2017-08-02 | 2023-04-21 | フェインズ セラピューティクス，インコーポレーテッド | 抗ｃｄ４７抗体及びその使用 |
| CN111051350B (zh) * | 2017-09-07 | 2022-11-01 | 苏州丁孚靶点生物技术有限公司 | 包含信号调节蛋白α的免疫缀合物 |
| SG11202006610YA (en) | 2018-01-12 | 2020-08-28 | Amgen Inc | Pac1 antibodies and uses thereof |
| WO2020113403A1 (en) * | 2018-12-04 | 2020-06-11 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
| WO2019147837A2 (en) | 2018-01-24 | 2019-08-01 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
| CN112912103B (zh) * | 2018-05-21 | 2025-08-29 | 广州邦定生物技术有限公司 | 多价蛋白质复合物 |
| US11634490B2 (en) | 2018-06-15 | 2023-04-25 | Accurus Biosciences, Inc. | Blocking antibodies against CD47 and methods of use thereof |
| SG11202012338QA (en) | 2018-07-10 | 2021-01-28 | Univ Kobe Nat Univ Corp | ANTI-SIRPa ANTIBODY |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN110540589B (zh) * | 2019-01-08 | 2021-07-20 | 西南大学 | 一种多肽、多肽修饰的脂质载体及应用 |
| CN114126648A (zh) | 2019-05-31 | 2022-03-01 | Alx肿瘤生物技术公司 | 用SIRPα Fc融合体组合免疫检查点抑制剂治疗癌症的方法 |
| US20200400662A1 (en) | 2019-06-07 | 2020-12-24 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| PH12022550326A1 (en) | 2019-08-13 | 2023-03-13 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
| ES2973832T3 (es) | 2019-10-18 | 2024-06-24 | Forty Seven Inc | Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda |
| JP2022552748A (ja) | 2019-10-31 | 2022-12-19 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療 |
| FI4065585T3 (fi) | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| CN121243368A (zh) | 2019-11-27 | 2026-01-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| TW202317190A (zh) | 2021-06-29 | 2023-05-01 | 美商思進公司 | 以非岩藻糖基化抗ｃｄ７０抗體及ｃｄ４７拮抗劑之組合治療癌症之方法 |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| KR20240165995A (ko) | 2022-03-24 | 2024-11-25 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암의 치료를 위한 병용요법 |
| US20250257113A1 (en) * | 2022-03-24 | 2025-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Multivalent sirp-alpha fusion polypeptides |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| KR20250028371A (ko) | 2022-07-01 | 2025-02-28 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CR20250446A (es) | 2023-04-21 | 2025-12-02 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121620513A (zh) | 2023-07-26 | 2026-03-06 | 吉利德科学公司 | Parp7抑制剂 |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| JP3670276B2 (ja) * | 1991-02-08 | 2005-07-13 | プロゲニクス・ファーマスーティカルズ、インコーポレイテッド | ＣＤ４― ガンマ・２キメラ及びＣＤ４ ― ＩｇＧ２・キメラ |
| US7070991B2 (en) * | 1991-02-08 | 2006-07-04 | Progenics Pharmaceuticals, Inc. | Cells expressing a CD4-IgG2 chimeric heterotetramer |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| DE19709861C2 (de) | 1997-03-11 | 1999-04-01 | Vitcon Projektconsult Gmbh | Einrichtung zur Ablation von Material mit Hilfe von Laserstrahlung |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| EP1244708B8 (en) | 1999-12-23 | 2007-03-07 | ZymoGenetics, Inc. | Method for treating inflammation |
| ES2252261T3 (es) | 2000-06-28 | 2006-05-16 | Glycofi, Inc. | Metodos para producir glicoproteinas modificadas. |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| WO2004084816A2 (en) * | 2003-03-21 | 2004-10-07 | Progenics Pharmaceuticals, Inc. | IMPROVED CD4-IgG2 FORMULATIONS |
| JP3936673B2 (ja) | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| JP2009537145A (ja) * | 2006-05-15 | 2009-10-29 | バイラル ロジック システムズ テクノロジー コーポレーション | 免疫学的疾患および障害を治療するためのｃｄ４７と関連した組成物および方法 |
| US8377448B2 (en) * | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| EP2573112A1 (en) | 2007-10-11 | 2013-03-27 | The Hospital For Sick Children | Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
-
2010
- 2010-12-21 BR BR112012017164A patent/BR112012017164A2/pt not_active IP Right Cessation
- 2010-12-21 JP JP2012545290A patent/JP2013514795A/ja active Pending
- 2010-12-21 CN CN2010800644263A patent/CN102939303A/zh active Pending
- 2010-12-21 TW TW099145049A patent/TW201130511A/zh unknown
- 2010-12-21 EP EP10795387A patent/EP2516458A1/en not_active Withdrawn
- 2010-12-21 AU AU2010334974A patent/AU2010334974A1/en not_active Abandoned
- 2010-12-21 WO PCT/EP2010/070355 patent/WO2011076781A1/en not_active Ceased
- 2010-12-21 KR KR1020127019187A patent/KR20120107122A/ko not_active Withdrawn
- 2010-12-21 MX MX2012007318A patent/MX2012007318A/es not_active Application Discontinuation
- 2010-12-21 US US13/517,989 patent/US20130011401A1/en not_active Abandoned
- 2010-12-21 CA CA2785139A patent/CA2785139A1/en not_active Abandoned
- 2010-12-22 AR ARP100104886A patent/AR079701A1/es unknown
- 2010-12-22 UY UY33132A patent/UY33132A/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN102939303A (zh) | 2013-02-20 |
| AR079701A1 (es) | 2012-02-15 |
| MX2012007318A (es) | 2012-07-20 |
| CA2785139A1 (en) | 2011-06-30 |
| EP2516458A1 (en) | 2012-10-31 |
| KR20120107122A (ko) | 2012-09-28 |
| TW201130511A (en) | 2011-09-16 |
| BR112012017164A2 (pt) | 2019-09-24 |
| AU2010334974A1 (en) | 2012-07-12 |
| JP2013514795A (ja) | 2013-05-02 |
| WO2011076781A1 (en) | 2011-06-30 |
| US20130011401A1 (en) | 2013-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY33132A (es) | Proteínas solubles para su uso terapéutico | |
| EP2621515A4 (en) | TOO HIGH SOLUBLE LEPTINE | |
| EP2744931A4 (en) | SOLUBLE POLYPEPTIDE | |
| BR112013008410A2 (pt) | sistema para uso em reparação tecidual | |
| BR112012013148A2 (pt) | formulação farmacêutica e uso | |
| BR112012003445A2 (pt) | aparelho dental sem o uso das maos para limpeza dos dentes | |
| BRPI1013432A2 (pt) | derivado de indolizina e uso do mesmo para propósitos médicos | |
| BRPI0915928A2 (pt) | composições e métodos de uso para anticorpos terapêuticos | |
| BRPI1012638A2 (pt) | métodos e intermediários para preparar agentes farmacêuticos | |
| BR112013004025A2 (pt) | amarra para uso hortícola | |
| PT2427212T (pt) | Anticorpos anti-cd100 e métodos para utilização dos mesmos | |
| BRPI1014572A2 (pt) | imidazoprazinas para uso como inibidores de cinase | |
| IL218865A (en) | Topical tetracycline compositions | |
| BRPI0911297A2 (pt) | composição e métodos para preparo e uso das mesmas | |
| BR112012004807A2 (pt) | vacina para pcsk9 | |
| BRPI1014464A2 (pt) | 4-ciano-3-benzoilamino-n-fenil-benzamidas para uso no controle de pragas | |
| BRPI0821668A2 (pt) | Uso | |
| SMT201400069B (it) | Formulazione farmaceutica | |
| BR112012001797A2 (pt) | composto bicíclico e uso do mesmo para propósitos médicos | |
| UY33094A (es) | Procedimiento para la preparacion de dronedarona | |
| BRPI1015367A2 (pt) | imidazotiodiazois para uso como inibidores de cinase | |
| FI20105640A7 (fi) | Menetelmä mikroselluloosan valmistamiseksi | |
| BRPI1005433A2 (pt) | preparações farmacêuticas transdérmicas | |
| BR112014002830A2 (pt) | fotossensibilizador para uso terapêutico | |
| DK2182988T3 (da) | Radiofarmaceutisk præparat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20181127 |